Shots:
- The US FDA has approved Rhapsido (remibrutinib) for the treatment of adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines
- Approval was based on SD cohort data of the P-III (RemIND) trial, where Rhapsido (PO) showed higher rates of complete response from hives at Wk. 12 vs PBO as measured by the Total Fric Score (29.3% vs 14%), with responses seen as early as Wk. 2
- Rhapsido (remibrutinib) is a highly selective BTK inhibitor that blocks the BTK pathway involved in histamine release, a key driver of hives & swelling
Ref: Globenewswire | Image: Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
